A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection

Table 2

Baseline characteristics, vital signs at the time of presentation to the hospital, and underlying comorbidities in comprehensive analysis colchicine and control groups (only including patients having at least two different timepoint measurements for at least two inflammatory markers (either D-dimer, CRP, LDH, or ferritin)). Age and pulse rate were normally distributed; the independent t-test was used to compare the two groups. BMI, temperature, oximetry (SpO₂), and respiratory rate were nonnormally distributed; the Mann–Whitney U test was used to compare the two groups. The χ² test was used to compare the gender, patients on room air, oxygen by a nasal cannula, a nonrebreather mask, the prevalence of HTN, DM, and renal failure in the two groups. Fisher’s exact test was used to compare the number of patients intubated at the time of presentation, the prevalence of asthma, COPD, hypothyroidism, and CAD in the two groups.

	Colchicine group (N = 34)	Control group (N = 78)	value
Demographics
Age (mean ± SD)	67.7 ± 12.3	66.4 ± 13.3	0.626
Gender, male (percentage)	21 (61.8)	40 (51.3)	0.306
BMI (median)	27.4	27.5	0.613
Vital signs at the time of presentation to the hospital
Pulse rate (mean ± SD)	99.7 ± 19.1	99.5 ± 20.9	0.973
Respiratory rate (median)	20	22	0.631
Temperature (median)	99.95	98.8	0.020
Initial SpO2 (median)	95.5	94	0.247
On room air when initial SpO2 obtained (percentage)	9 (26.5)	32 (41)	0.141
On oxygen by a nasal cannula when initial SpO2 obtained (percentage)	17 (50)	23 (29.5)	0.037
On a nonrebreather mask when initial SpO2 obtained (percentage)	7 (20.6)	19 (24.4)	0.664
Intubated when initial SpO2 obtained (percentage)	1 (2.9)	4 (5.1)	1.00
Comorbid illnesses
HTN	18 (52.9)	56 (71.8)	0.053
DM	11 (32.4)	40 (51.3)	0.064
Asthma	1 (2.7)	8 (10)	0.272
COPD	5 (14.7)	6 (7.7)	0.304
Hypothyroidism	3 (8.8)	3 (3.8)	0.365
CAD	2 (5.9)	6 (7.7)	1.00
Renal failure	12 (35.2)	47 (60.3)	0.015

HTN, hypertension; DM, diabetes mellitus; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; CKD, chronic kidney disease.